UBA2

PF3D7_1237000 (UBA2) encodes the large subunit of the P. falciparum SUMO-activating (E1) enzyme, functioning as part of the E1 heterodimer that initiates the parasite sumoylation cascade by activating PfSUMO and transferring it to the E2-conjugating enzyme Ubc9 to support substrate sumoylation, demonstrated in vitro with RanGAP1 as substrate (PMID:23943616). The E1–E2 interaction is species-specific: P. falciparum E1 engages P. falciparum Ubc9 but fails to productively interact with human E2, and reciprocally, a specificity traced by structural analysis and mutagenesis to divergent surface residues at the E1–E2 interface (PMID:23943616, PMID:26697886). Functionally, a mutation engineered into UBA2 confers high-level resistance to the benzoxaborole AN13762, establishing that UBA2 activity contributes to parasite susceptibility to this compound and that alterations in the sumoylation cascade constitute a resistance mechanism (PMID:31992618). Beyond its role as the E1 large subunit and its E1–E2 interface specificity, the endogenous substrate repertoire, regulation, and cellular localization of PF3D7_1237000 have not been characterized in the available corpus.

1. 2013 High

   Established that P. falciparum UBA2, as part of the SUMO E1 heterodimer, activates and transfers SUMO to Ubc9 through a binding interface that is organism-specific rather than universal, revealing a potential selectivity handle distinguishing parasite from host sumoylation.

   Evidence In vitro reconstituted sumoylation assay with RanGAP1 substrate plus heterologous cross-species E1–E2 interaction assays and structural/binding analysis

   PMID:23943616

   Open questions at the time

   • Endogenous parasite substrates beyond the RanGAP1 model reaction not identified
   • Relative contributions of the E1 large versus small subunit not resolved
   • Cellular localization and expression timing of UBA2 not addressed
2. 2015 High

   Pinpointed the specific surface residues at the UBA2-containing E1–E2 interface responsible for species-specific enzyme pairing, defining the structural basis for parasite-versus-human selectivity.

   Evidence X-ray crystallography of the human E1 UFD–Ubc9 complex combined with in silico modeling, site-directed mutagenesis of the P. falciparum E1, and in vitro biochemical assays

   PMID:26697886

   Open questions at the time

   • No direct crystal structure of the P. falciparum E1–E2 complex reported
   • Whether interface residues are exploitable for selective inhibitor design not tested
3. 2020 Medium

   Connected UBA2 function to drug response by showing that a UBA2 mutation confers resistance to the benzoxaborole AN13762, implicating the sumoylation pathway in the parasite's compound susceptibility.

   Evidence In vitro resistance selection, whole-genome sequencing, and reintroduction of the specific mutation followed by IC50 measurement

   PMID:31992618

   Open questions at the time

   • Mechanism by which the mutation alters AN13762 susceptibility (target engagement vs. pathway flux) not defined
   • Whether AN13762 directly targets UBA2 not established
   • Single method for the UBA2-specific resistance finding
4. 2022 Low

   Refined the species-specificity picture by showing asymmetric cross-species compatibility in the pathway UBA2 initiates, with Pf-SUMO able to engage human Ubc9 while human SUMO1 cannot engage Pf-Ubc9.

   Evidence Biochemical interaction and biophysical analyses with mutagenesis, focused on PfSUMO and Pf-Ubc9

   PMID:35331687

   Open questions at the time

   • UBA2/E1 itself was not directly assayed in this study, so implications for UBA2 activation step are inferential
   • Directionality of specificity not tested in a fully reconstituted parasite cascade
   • Single lab, single study

• The endogenous sumoylation substrates, in-cell regulation, and lifecycle-stage functions of PF3D7_1237000 remain undefined, as does the precise mechanistic basis linking UBA2 activity to benzoxaborole susceptibility.
• No parasite-wide sumoylation substrate map attributed to UBA2 activity
• No structure of the intact P. falciparum E1 heterodimer
• No genetic essentiality or knockdown phenotype for UBA2 in the corpus